Loading
Athna Biotech
Athna Biotech develops nanomedicines, tiny drug-carrying particles, including one for early bladder cancer and one activated by radiotherapy for lung cancer. Both are in laboratory development.
Also called: Athna Biotech, Inc.ATHNA BIOTECH, INC.
Overview
Athna Biotech develops nanomedicine and drug delivery platforms and carries them through preclinical development. Its news page records NCI awards to develop a salt-based nanomedicine for non-muscle invasive bladder cancer. In fiscal year 2026 NCI awarded it USD 937,492 under STTR award 2R42CA262399-02 for the bladder cancer nanomedicine and USD 1,098,560 under STTR award 5R42CA257584-03 for a radiation-activatable nanoparticle for lung cancer.
Headquarters
Athens, GA, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI STTR award (R42) 2R42CA262399-02: Development of a salt-based nanomedicine for non-muscle invasive bladder cancer | 2026 | $937K | reporter.nih.gov |
| Grant · NCI STTR award (R42) 5R42CA257584-03: Development of a radiation-activatable nanoparticle for lung cancer therapy | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
- No named product on the company website. Read on athnabiotech.com and NIH RePORTER on 4 November 2026.
Connected
4Similar pages
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
athnabiotech.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/